肿瘤相关巨噬细胞通过激活CCL22-CCR4轴促进前列腺癌迁移。
Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis.
作者信息
Maolake Aerken, Izumi Kouji, Shigehara Kazuyoshi, Natsagdorj Ariunbold, Iwamoto Hiroaki, Kadomoto Suguru, Takezawa Yuta, Machioka Kazuaki, Narimoto Kazutaka, Namiki Mikio, Lin Wen-Jye, Wufuer Guzailinuer, Mizokami Atsushi
机构信息
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Immunology Research Center, National Health Research Institutes, Zhunan, Miaoli County, Taiwan.
出版信息
Oncotarget. 2017 Feb 7;8(6):9739-9751. doi: 10.18632/oncotarget.14185.
Previous studies have found that tumor-associated macrophages (TAMs) promote cancer progression. We previously reported that TAMs promote prostate cancer metastasis via activation of the CCL2-CCR2 axis. The CCR4 (receptor of CCL17 and CCL22) expression level in breast cancer was reported to be associated with lung metastasis. The aim of this study was to elucidate the role of CCR2 and CCR4 in prostate cancer progression. CCR2 and CCR4 were expressed in human prostate cancer cell lines and prostate cancer tissues. In vitro co-culture of prostate cancer cells and macrophages resulted in increased CCL2 and CCR2 levels in prostate cancer cells. The addition of CCL2 induced CCL22 and CCR4 production in prostate cancer cells. The migration and invasion of prostate cancer cells via enhanced phosphorylation of Akt were promoted by CCL17 and CCL22. CCR4 may be a potential candidate for molecular-targeted therapy.
先前的研究发现，肿瘤相关巨噬细胞（TAM）可促进癌症进展。我们之前报道过，TAM通过激活CCL2-CCR2轴促进前列腺癌转移。据报道，乳腺癌中CCR4（CCL17和CCL22的受体）的表达水平与肺转移有关。本研究的目的是阐明CCR2和CCR4在前列腺癌进展中的作用。CCR2和CCR4在人前列腺癌细胞系和前列腺癌组织中表达。前列腺癌细胞与巨噬细胞的体外共培养导致前列腺癌细胞中CCL2和CCR2水平升高。添加CCL2可诱导前列腺癌细胞产生CCL22和CCR4。CCL17和CCL22通过增强Akt的磷酸化促进前列腺癌细胞的迁移和侵袭。CCR4可能是分子靶向治疗的潜在候选靶点。
Zotero 插件